Ozmosi | Avexitide Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

Avexitide

Pronounced as: a-VEX-i-tide

Alternative Names: Avexitide, exendin-(9-39), exendin (9-39), exendin 9-39, exendin(9-39)amide, exendin-9,39, exendin9,39, exendin 9,39, EXENDIN-3
Clinical Status: Active
Latest Update: 2026-05-13
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: GLP-1 Antagonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous, Subcutaneous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Eiger BioPharmaceuticals
Company Location:
Company Founding Year: 2008
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Avexitide

Countries in Clinic: United States

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

  • Clinical Outcomes Expected - Amylyx announced they will present P3 Hypoglycemia results in 3Q26 for Avexitide
  • Clinical Outcomes Reported - Amylyx presented P3 Hypoglycemia results on 2026-06-14 for Avexitide

Highest Development Phases

Phase 3: Hypoglycemia

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06747468

 LUCIDITY

P3

Active, not recruiting

Hypoglycemia

2026-03-01

7%

2026-03-05

Primary Endpoints

Recent News Events

Date

Type

Title

03/24/2026

News Article

 Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

02/06/2019

News Article

 Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan

02/04/2019

News Article

 Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions